This MedLibrary.org supplementary page on Methyldopa is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Methyldopa
|
|
| Systematic (IUPAC) name | |
| 2-amino-3-(3,4-dihydroxyphenyl)-2-methyl-propanoic acid | |
| Identifiers | |
| CAS number | |
| ATC code | C02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C10H13NO4 |
| Mol. mass | 211.215 g/mol |
| Pharmacokinetic data | |
| Bioavailability | approximately 50% |
| Metabolism | Hepatic |
| Half life | 105 minutes |
| Excretion | Renal for metabolites |
| Therapeutic considerations | |
| Pregnancy cat. |
a drug of choice in PIH |
| Legal status |
℞ Prescription only |
| Routes | Oral, IV |
Methyldopa or alpha-methyldopa (brand names Aldomet, Apo-Methyldopa, Dopamet, Novomedopa) is a centrally-acting adrenergic antihypertensive medication. Its use is now deprecated following introduction of alternative safer classes of agents. However it continues to have a role in otherwise difficult to treat hypertension and pregnancy-induced hypertension.
Contents |
Pharmacokinetics
Methyldopa has variable absorption from the gut of approximately 50%. It is metabolized in the intestines and liver; its metabolite alpha-methylnorepineprine acts in the brain to stimulate alpha-adrenergic receptors decreasing total peripheral resistance. It is excreted in urine.
Mechanism of action
Methyldopa, in its active metabolite form, is a central alpha-2 receptor agonist. Using methyldopa leads to alpha-2 receptor-negative feedback to sympathetic nervous system (SNS) (centrally and peripherally), allowing peripheral sympathetic nervous system (PSNS) tone to decrease. Such activity leads to a decrease in total peripheral resistance (TPR) and cardiac output.
Rebound effect
Rebound hypertension has been reported in some cases when methyldopa has been abruptly withdrawn after extended use[1]. This results because the long term use of methyldopa lowers the sensitivity of presynaptic alpha 2 receptors: the release of norepinephrine (NE) from sympathetic nerve endings is modulated by NE itself acting on the presynaptic alpha 2 autoreceptors thus inhibiting its own release. The discontinuation of methyldopa removes the inhibition on NE release leading to excessive NE release from the SNS and the rebound hypertension.
History
When introduced it was a mainstay of antihypertensive therapy, but its use has declined, with increased use of other safer classes of agents. One of its important present-day uses is in the management of pregnancy-induced hypertension, as it is relatively safe in pregnancy compared to other antihypertensive drugs.
Side effects
There are many possible reported side-effects with some, whilst rare, being serious. Side effects are usually fewer if the dose is less than 1 g per day:[2]
- Gastro-intestinal disturbances
- Dry mouth
- Bradycardia (slow pulse rate)
- Worsening of angina
- Orthostatic hypotension (Postural hypotension)
- Sedation, headaches, dizziness
- Myalgia (muscle pain), arthralgia (joint pain) or paraesthesia (numbness)
- Nightmares, mild psychosis, depression
- Parkinsonism
- Bell's palsy
- Abnormal liver functions tests and hepatitis
- Pancreatitis
- Haemolytic anaemia
- Bone marrow suppresion leading to thrombocytopenia (low platelets) or leucopenia (low white blood cells)
- Hypersensitivity reactions including lupus erythematosus-like syndrome, myocarditis (heart muscle inflammation), pericarditis and rashes
- Ejaculatory failure, Impotence, decreased libido, gynecomastia (breast enlargement in men), hyperprolactinaemia and amenorrhoea
- Note that if used in pregnant women, it may cause a positive Coombs test
Footnotes
- ^ http://www.inchem.org/documents/pims/pharm/methyldo.htm
- ^ British National Formulary 45 March 2003
|
||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 12 June 2008, at 02:21.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Methyldopa".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.